Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Cody

Gastroenterology Tampa, FL Medical Doctor

NPI 1376658039 CMS profile 289770

14547 Bruce B Downs Blvd Ste A, Tampa, FL 33613

Open in the dashboard

General payments

$12,534

650 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Cody of Tampa, FL is reported in the CMS Open Payments database as having received $12,534 across 650 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,101 69
2024 General $1,907 92
2023 General $2,135 101
2022 General $2,150 120
2021 General $1,647 108
2020 General $1,477 100
2019 General $1,117 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Cody
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Joseph Cody were reported at $2,101. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Joseph Cody Gastroenterology median Middle half National median
2019 $1,117 $417 $126–$1,100 $163
2020 $1,477 $224 $74–$624 $114
2021 $1,647 $352 $106–$1,054 $132
2022 $2,150 $448 $129–$1,270 $149
2023 $2,135 $533 $150–$1,390 $160
2024 $1,907 $605 $160–$1,606 $164
2025 $2,101 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,343 178 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,514 95 payments
  3. Janssen Biotech, Inc. $1,169 67 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $850 48 payments
  5. Boston Scientific Corporation $783 13 payments
  6. Genzyme Corporation $586 23 payments
  7. RedHill Biopharma Inc. $578 31 payments
  8. Gilead Sciences, Inc. $563 26 payments
  9. Celgene Corporation $471 32 payments
  10. Pfizer Inc. $398 21 payments
  11. Other $2,280 116 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,985 642 payments
  2. Travel and Lodging $358 1 payment
  3. Education $191 7 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,316 79 payments
  2. CREON $1,117 73 payments
  3. LINZESS $1,102 70 payments
  4. STELARA $1,084 61 payments
  5. MAVYRET $705 31 payments
  6. RINVOQ $622 26 payments
  7. ENTYVIO $601 28 payments
  8. DUPIXENT $586 23 payments
  9. Talicia $551 29 payments
  10. SKYRIZI $520 20 payments
  11. Other $8,221 423 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,010

Median for Gastroenterology: 569

Drug cost

$271,494

Median for Gastroenterology: $104,976

Branded share of claims

27.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 45 $158,020
Linzess Linaclotide Brand 34 $35,776
Pancreaze Lipase/Protease/Amylase Brand 13 $30,205
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 116 $7,705
Mesalamine Generic 13 $5,264
Mesalamine Er Mesalamine Brand 25 $5,228
Pantoprazole Sodium Generic 389 $5,062
Dexlansoprazole Dr Dexlansoprazole Brand 12 $4,630
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 25 $4,269
Ursodiol Generic 14 $3,907

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$74,980

Medicare's payments for the services billed

Medicare patients

444

Average age 73

Services billed

673

249 women, 195 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 33%
Ischemic heart disease 32%
Chronic kidney disease 26%
Depression 24%
Cancer 21%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $183
$183 — —
DUPIXENT
  • GENZYME CORPORATION $178
$178 — —
OMVOH
  • Lilly USA, LLC $137
$137 — —
LINZESS
  • AbbVie, Inc. $123
$123 34 —
CREON
  • AbbVie, Inc. $123
$123 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

650 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record